Ursula A Matulonis

No ORCID on file · 4 papers in corpus · active 2016-2025

Study types

  • article 3
  • other 1

Condition tags

  • endometriosis 2
other 2025
Validation of Tumor Budding as a Prognostic Factor in Ovarian Clear Cell Carcinoma Using an Independent Cohort
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists ·doi:10.1097/PGP.0000000000001099

Ovarian clear cell carcinoma (OCCC) is an endometriosis-related neoplasm, in which traditional histologic grading does not show prognostic significance. Tumor budding was associated with poorer outcomes in OCCC in previous studies. We aimed…

article 2024
TP005/#1564  Gog-3069: phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor-positive endometrioid endometrial cancers
·doi:10.1136/ijgc-2024-igcs.607
article 2021
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
·doi:10.1200/jco.2021.39.15_suppl.tps5609

TPS5609 Background: Despite significant strides in understanding the molecular pathogenesis of EC, there remain few effective therapies for recurrent disease. Deeper insight into the roles of disordered tumor vasculature and HIF1α- and VEGF…

article 2016
Immunogenicity of clear cell ovarian cancer: Association with ARID1A loss, microsatellite instability and endometriosis.
·doi:10.1200/jco.2016.34.15_suppl.5514

5514 Background: Studies of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) in ovarian cancer have demonstrated isolated responses in tumors with clear cell histology. In order to assess the immunogenicity of clear cell ovar…